Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737639 | 0.97 | HRH3 (0.63) | HRH3KCNH2 | |
| SCHEMBL4468194 | 0.93 | HRH3 (0.58) | HRH3KCNH2 | |
| SCHEMBL17533980 | 0.92 | HRH3 (0.58) | HRH3KCNH2 | |
| SCHEMBL18284038 | 0.85 | HRH3 (0.51) | HRH3KCNH2 | |
| SCHEMBL16712653 | 0.81 | HRH3 (0.61) | HRH3KCNH2 | |
| SCHEMBL2822372 | 0.81 | HRH3 (0.61) | HRH3KCNH2 | |
| SCHEMBL747626 | 0.81 | PARP10 (0.55) | HRH3 | |
| SCHEMBL2005824 | 0.81 | HRH3 (0.61) | HRH3KCNH2 | |
| SCHEMBL5203744 | 0.81 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL12484261 | 0.81 | HRH3 (0.57) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856719-B1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPHARMA LTD (KY) | 2023-06-07 | — | — | EP | disclosed |
| US-20220380339-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2022-12-01 | — | — | US | disclosed |
| CN-114042070-A | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-112004802-B | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-20210188808-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-06-24 | — | — | US | disclosed |
| US-10968202-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XW LABORATORIES INC. (KY) | 2021-04-06 | — | — | US | disclosed |
| US-20200369645-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2020-11-26 | — | — | US | disclosed |
| US-10730853-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XW LABORATORIES INC. (KY) | 2020-08-04 | — | — | US | disclosed |
| US-20200181112-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2020-06-11 | — | — | US | disclosed |
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8268842-B2 | Fused ring 4-oxopyrimidine derivative | MSD K.K. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1311482-B1 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380339-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 763/4885 |
| US-20200181112-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 499/4885 |
| US-10968202-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 499/4885 |
| US-20200369645-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 499/4885 |
| US-20210188808-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 499/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | HRH3 3/4885KCNH2 299/4885 |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | HRH3 3/4885KCNH2 299/4885 |
| US-10730853-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.